Life years lost and cardiovascular risk in type 2 diabetes patients requiring glucose-lowering treatment 2008-2015: nationwide data from Norway and Sweden

被引：0

作者：

Gulseth, H. L. ^{[1
]}

Bodegard, J. ^{[2
]}

Norhammar, A. ^{[3
]}

Nathanson, D. ^{[4
]}

Thuresson, M. ^{[5
]}

Birkeland, K. I. ^{[6
]}

Eriksson, J. W. ^{[7
]}

Nystrom, T. ^{[4
]}

机构：

[1] Oslo Univ Hosp, Oslo, Norway

[2] AstraZeneca Nord Balt, Sodertalje, Sweden

[3] Karolinska Inst, Stockholm, Sweden

[4] Soder Sjukhuset, Stockholm, Sweden

[5] Statisticon AB, Uppsala, Sweden

[6] Univ Oslo, Oslo, Norway

[7] Uppsala Akad Sjukhus, Uppsala, Sweden

来源：

DIABETOLOGIA | 2017年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

293

引用

页码：S136 / S137

页数：2

共 50 条

[1] Time-trends in incidence and prevalence of type 2 diabetes patients requiring glucose-lowering treatment from 2007-2015: nationwide data from Norway and Sweden
Nathanson, D.
Bodegard, J.
Norhammar, A.
Birkeland, K. I.
Nystrom, T.
Thuresson, M.
Eriksson, J. W.
Gulseth, H. L.
DIABETOLOGIA, 2017, 60 : S169 - S169
[2] Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013
Anna Norhammar
Johan Bodegård
Thomas Nyström
Marcus Thuresson
Jan W. Eriksson
David Nathanson
Diabetologia, 2016, 59 : 1692 - 1701
[3] Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Norhammar, Anna
Bodegard, Johan
Nystrom, Thomas
Thuresson, Marcus
Eriksson, Jan W.
Nathanson, David
DIABETOLOGIA, 2016, 59 (08) : 1692 - 1701
[4] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, Rita R.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1248 - 1260
[5] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Donnelly, Peter E.
Winch, Denis E.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07): : 670 - 671
[6] Glucose-lowering treatment influences risk of death in patients with diabetes: a nationwide study
Schramm, T. K.
Gislason, G.
Rasmussen, S.
Rasmussen, J. N.
Folke, F.
Hansen, M. L.
Fosbol, E. L.
Kober, L.
Torp-Pedersen, C.
Vaag, A.
EUROPEAN HEART JOURNAL, 2008, 29 : 140 - 140
[7] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Prattichizzo, Francesco
La Sala, Lucia
Ryden, Lars
Marx, Nikolaus
Ferrini, Marc
Valensi, Paul
Ceriello, Antonio
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
[8] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
Rozalina G. McCoy
Jeph Herrin
Kavya Sindhu Swarna
Yihong Deng
David M. Kent
Joseph S. Ross
Guillermo E. Umpierrez
Rodolfo J. Galindo
William H. Crown
Bijan J. Borah
Victor M. Montori
Juan P. Brito
Joshua J. Neumiller
Mindy M. Mickelson
Eric C. Polley
Nature Cardiovascular Research, 2024, 3 : 431 - 440
[9] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
Mccoy, Rozalina G.
Herrin, Jeph
Swarna, Kavya Sindhu
Deng, Yihong
Kent, David M.
Ross, Joseph S.
Umpierrez, Guillermo E.
Galindo, Rodolfo J.
Crown, William H.
Borah, Bijan J.
Montori, Victor M.
Brito, Juan P.
Neumiller, Joshua J.
Mickelson, Mindy M.
Polley, Eric C.
NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (04): : 431 - 440
[10] Differences in risk of cardiovascular death according to type of oral glucose-lowering therapy in patients with diabetes: a nationwide study
Schramm, Tina Ken
Gislason, Gunnar H.
Vaag, Allan
Rasmussen, Jeppe N.
Folke, Fredrik
Hansen, Morten L.
Fosbol, Emil L.
Jorgensen, Casper H.
Norgaard, Mette L.
Kober, Lars
Torp-Pedersen, Christian
CARDIOLOGY, 2009, 113 : 59 - 59

← 1 2 3 4 5 →